Explore Watchlists Pricing

LIGAND PHARMACEUTICALS INC (LGND) Income statement

Market cap

$4.7B

P/E ratio

38.2x

Summary Financials

Income statement Balance sheet Cash flow Other

	2011/12	2012/12	2013/12	2014/12	2015/12	2016/12	2017/12	2018/12	2019/12	2020/12	2021/12	2022/12	2023/12	2024/12	2025/12
Revenue	30	31	49	65	72	109	141	251	120	186	277	196	131	167	268
Revenue growth (%)	-
Cost of revenue	5	4	6	9	6	6	5	6	11	30	62	53	11	11	15
Research & development	10	11	9	12	13	21	27	28	56	59	69	36	25	21	81
Operating margin (%)
Operating income	-1	1	15	20	27	44	68	164	807	26	79	3	12	-23	41
Income before tax	-3	-4	9	11	35	8	57	173	797	-11	47	36	64	3	159
Pretax margin (%)	-9.8	-12.3	18.8	17.5	49.1	7.3	40.6	68.9	662.3	-5.7	17.1	18.4	48.5	1.5	59.3
Provision for income taxes	-13	-	0	0	-220	10	45	30	167	-8	-10	41	10	7	35
Effective tax rate (%)		-
Net income	10	-1	11	12	257	-2	13	143	629	-3	57	-33	52	-4	124
Net income margin (%)
Earnings per share	-	-	0.56	0.59	13	-0.08	0.6	6.77	33.13	-0.18	3.44	-1.98	3.02	-0.22	6.44
Diluted EPS	-	-	0.55	0.56	12.12	-0.08	0.53	5.96	31.85	-0.18	3.31	-1.98	2.94	-0.22	6.13
EBITDA
EBITDA margin (%)